Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.47 |
| ▸ | ITGAV | P06756 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7260872 | 0.97 | PTGER4 (0.49) | PTGER4ITGB3ITGAVATMCTSL | |
| SCHEMBL7358758 | 0.84 | PTGER4 (0.58) | PTGER4ITGB3ITGAVTPSAB1CTSL | |
| SCHEMBL4413420 | 0.84 | PTGER4 (0.58) | PTGER4ITGB3ITGAVTPSAB1CTSL | |
| SCHEMBL6887132 | 0.84 | NPY4R (0.48) | — | |
| SCHEMBL5419016 | 0.81 | PTGER4 (0.55) | PTGER4ITGB3ITGAVTPSAB1CTSL | |
| SCHEMBL8495773 | 0.81 | PTGER4 (0.55) | PTGER4ITGB3ITGAVTPSAB1CTSL | |
| SCHEMBL7355085 | 0.81 | PTGER4 (0.55) | PTGER4ITGB3ITGAVTPSAB1CTSL | |
| SCHEMBL11411256 | 0.81 | CTSL (0.56) | PTGER4ITGB3ITGAVCTSLCTSS | |
| SCHEMBL24838023 | 0.80 | CA1 (0.58) | PTGER4TPSAB1CTSLSMN1; SMN2CTSS | |
| SCHEMBL7698946 | 0.80 | PTGER4 (0.53) | PTGER4CTSLCTSSSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030133972-A1 | Targeted multivalent macromolecules | TARGESOME, INC. | 2003-07-17 | — | — | US | disclosed |
| US-20030129223-A1 | Therapeutic agents, comprising a linking carrier, a therapeutic entity associated with the linking carrier, and atleast one targeting entity | TARGESOME, INC. | 2003-07-10 | — | — | US | disclosed |
| WO-1999057273-A2 | CYTOPLASMIC ANTIPROTEINASE-3 CODING SEQUENCE IN GENE THERAPY | ZYMOGENETICS (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030133972-A1 | Targeted multivalent macromolecules | CLTB, ILK, CD44 | PTGER4 4852/4885ITGB3 290/4885ITGAV 72/4885 |
| US-20030129223-A1 | Therapeutic agents, comprising a linking carrier, a therapeutic entity associated with the linking carrier, and atleast one targeting entity | CD47, TSG101, ILK | PTGER4 4447/4885ITGB3 831/4885ITGAV 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.